MN-221

DRUG3 trials

Sponsors

MediciNova

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 1

Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT01551316

MediciNovaChronic Obstructive Pulmonary Disease

Start: 2012-03-31End: 2012-05-31Updated: 2012-05-21

Phase 2

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

CompletedNCT00679263

MediciNovaAsthma

Start: 2008-02-29End: 2008-07-31Updated: 2011-12-19

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

CompletedNCT00838591

MediciNovaAsthma

Start: 2009-03-31End: 2012-03-31Updated: 2013-09-05

Related Papers

Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma.

2015-08-143 citations

Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion.

2012-10-257 citations